Drug Overview

Samotolisib is a highly advanced, experimental medication designed to fight various types of cancer, including prostate cancer, breast cancer, and other solid tumors. Because it is a powerful laboratory-created molecule that acts inside the cancer cells, it is currently being evaluated in clinical trials worldwide to determine its safety and effectiveness.

As an investigational drug, samotolisib is not yet available at standard pharmacies. It is only accessible to patients who are formally enrolled in approved medical research studies.

• Generic name: Samotolisib (also known in research as LY3023414)
• US Brand names: None (Investigational drug)
• Drug Class: Dual PI3K and mTOR inhibitor, Small molecule kinase inhibitor
• Route of Administration: Oral (taken by mouth as a tablet or capsule)
• FDA Approval Status: Investigational (Not currently approved by the FDA for standard medical use)

What Is It and How Does It Work? (Mechanism of Action)

Samotolisib represents a modern approach to cancer treatment, possessing strong Targeted Therapy and Smart Drug characteristics. Rather than indiscriminately attacking all rapidly dividing cells like traditional chemotherapy, this medication is precision-engineered to locate and block specific abnormal communication pathways that cancer cells rely on to survive, grow, and spread.

At the molecular level, samotolisib works by blocking two critical enzymes inside the cell: phosphoinositide 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR). In healthy cells, the PI3K/AKT/mTOR signaling pathway acts as a normal control center for cell growth and energy use. However, in many cancers, genetic mutations (such as PIK3CA mutations or the loss of the PTEN tumor suppressor gene) cause this pathway to become permanently stuck in the “on” position. This runaway signaling tells the cancer cells to multiply rapidly and resist natural cell death.

Samotolisib is an ATP-competitive inhibitor that binds directly to class I PI3K isoforms as well as both mTOR complexes (mTORC1 and mTORC2). By simultaneously inhibiting both PI3K and mTOR, the drug effectively shuts down the entire signaling cascade. This dual-blockade is crucial because older drugs that only blocked one part of the pathway often failed; the cancer cells would simply use a “feedback loop” to reactivate the pathway through the unblocked protein. By blocking both escape routes, samotolisib forcefully halts cancer cell division and triggers apoptosis (programmed cell death).

FDA-Approved Clinical Indications

Because samotolisib is an investigational medication, it does not currently have official FDA-approved indications. It is, however, being rigorously evaluated in clinical trials for the following conditions:

Oncological uses

• Investigational treatment for metastatic castration-resistant prostate cancer.
• Investigational treatment for advanced solid tumors, including endometrial cancer and triple-negative breast cancer.
• Investigational treatment for squamous non-small cell lung cancer.

Non-oncological

• None at this time.

Dosage and Administration Protocols

As an experimental therapy, the exact dosage of samotolisib is strictly dictated by the specific clinical trial protocol. The table below outlines the standard dosing framework observed in recent Phase 1 and Phase 2 trials.

Dose Adjustments

If a patient experiences severe side effects or toxicity (such as severe drops in blood cell counts or liver enzyme elevations), clinical trial protocols mandate strict dose adjustments. Typically, the dose is reduced from 200 milligrams twice daily to 150 milligrams twice daily. Because samotolisib is metabolized by the liver (specifically via the CYP3A4 enzyme), patients with significant hepatic insufficiency or those taking medications that interfere with liver enzymes may require careful dose modifications or may be excluded from certain trials.

Clinical Efficacy and Research Results

Recent clinical trial data from the 2020 to 2025 period have highlighted samotolisib’s potential, particularly when combined with other targeted therapies.

In a notable 2022 Phase 2 study involving men with metastatic castration-resistant prostate cancer whose disease had progressed after taking abiraterone, patients were given a combination of samotolisib and enzalutamide. The group receiving samotolisib demonstrated a median radiographic progression-free survival of 10.2 months, compared to only 5.5 months for the group receiving enzalutamide alone. Furthermore, in patients lacking a specific genetic resistance marker (the androgen receptor splice variant 7), the progression-free survival extended to a highly encouraging 13.2 months.

In other Phase 1b trials for advanced solid tumors, including triple-negative breast cancer, samotolisib showed an overall response rate of approximately 15 percent to 25 percent in heavily pretreated patient populations when used in combination with other DNA-damaging agents. While larger Phase 3 trials are still needed to confirm overall survival rates, these numerical outcomes suggest that samotolisib can significantly delay disease progression in difficult-to-treat cancers.

Safety Profile and Side Effects

Like all potent targeted therapies, samotolisib carries a risk of side effects, which are closely monitored by the clinical trial medical team.

Black Box Warning

Because samotolisib is an investigational drug and not available on the open market, it does not yet carry an official FDA Black Box Warning.

Common side effects

The following side effects have been reported in greater than 10 percent of patients in early clinical trials:

• Decreased white blood cell counts (leukopenia and neutropenia), which occurred in over 90 percent of patients in some combination trials, increasing the risk of infection.
• Decreased blood platelet counts (thrombocytopenia), seen in over 60 percent of patients, increasing the risk of bruising and bleeding.
• Nausea, vomiting, and decreased appetite.
• Fatigue and general weakness.
• Elevated blood sugar levels (hyperglycemia), which is a known effect of blocking the PI3K pathway.

Serious adverse events

• Severe mucositis (painful inflammation and ulceration of the digestive tract).
• Pneumonitis (non-infectious inflammation of the lung tissue causing breathing difficulties).
• Severe bone marrow suppression leading to critical infections or bleeding events.

Management strategies

Patient safety is maintained through proactive management strategies. For nausea and gastrointestinal distress, doctors frequently prescribe anti-nausea medications. To manage elevated blood sugar, patients may need dietary changes or oral anti-diabetic medications (like metformin) during the trial. If blood cell counts drop to dangerous levels, the medical team will temporarily pause the samotolisib treatment until the bone marrow recovers, and then restart the medication at a lower dose.

Research Areas

While there is no established protocol combining samotolisib with stem cell transplants, the drug is highly relevant to cancer stem cell research. The PI3K/mTOR pathway is frequently used by cancer stem cells to resist chemotherapy and radiation. By cutting off this crucial survival pathway, researchers are investigating whether samotolisib can eliminate these stubborn root cells, potentially preventing the cancer from returning after the main tumor is destroyed.

Patient Management and Practical Recommendations

Patients participating in a samotolisib clinical trial must adhere to comprehensive safety and monitoring guidelines.

Pre treatment tests to be performed

• Comprehensive blood tests, including a complete blood count to check baseline white blood cells, red blood cells, and platelets.
• Fasting blood glucose and Hemoglobin A1c tests to ensure the patient does not have uncontrolled diabetes.
• Liver and kidney function panels to confirm the organs can safely metabolize the drug.
• An electrocardiogram to evaluate the baseline electrical activity of the heart.

Precautions during treatment

Patients must be highly vigilant about their risk of infection due to the potential for lowered white blood cell counts. Even a minor fever should be treated as a medical emergency. Additionally, because the drug can cause blood sugar spikes, patients will need to monitor their glucose levels regularly, even if they have never been diagnosed with diabetes.

Do’s and Don’ts list

• Do take the medication exactly as prescribed by your clinical trial team, usually at the same times each day.
• Do report any signs of lung inflammation, such as a new, dry cough or shortness of breath, to your oncologist immediately.
• Do maintain excellent oral hygiene to reduce the risk and severity of mouth sores (mucositis).
• Don’t consume grapefruit or grapefruit juice, as it can severely interfere with the liver enzymes (CYP3A4) responsible for clearing the drug from your body.
• Don’t start any new over-the-counter medications, herbal supplements, or vitamins without explicitly clearing them with your research doctor first.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Samotolisib (LY3023414) is an investigational medication and is not approved by the Food and Drug Administration to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional or your clinical trial oncologist before making any decisions regarding your cancer treatment, managing side effects, or participating in a clinical research study.